CD106 Antibody [1.G11B1] (Biotin) | 99-410

CD106 Antibody [1.G11B1] (Biotin) | 99-410 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Pig

Homology: N/A

Immunogen: N/A

Research Area: Cancer, Neuroscience, Signal Transduction

Tested Application: Flow

Application: CD106 Antibody [1.G11B1] for use in flow cytometry, immunohistochemistry / immunocytochemistry, western blotting, immunoprecipitation, and ELISA assays.

Specificiy: CD106

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: [1.G11B1]

Isotype: IgG1

Conjugate: Biotin

Physical State: Liquid

Buffer: Supplied in PBS/NaN3

Concentration: Lot specific

Storage Condition: Store vial at 2-8˚C

Alternate Name: VCAM-1, INCAM-110, vascular cell adhesion molecule-1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CD106, also known as INCAM-110, is a 110 kDa vascular adhesion cell adhesion molecule-1 (VCAM-1) that is member of the immunoglobulin superfamily. CD106 is expressed predominantly on cytokine-activated vascular endothelium but has also been identified on interfollicular dendritic cells, some macrophages, and bone marrow stromal cells. Endothelial CD106 binds the integrins alpha4beta1 (CD49d/CD29, VLA-4) and alpha4beta7 and contributes to extravasation of lymphocytes, monocytes, basophils, and eosinophils (but not neutrophils) from blood vessels, particularly at sites of inflammation. Unlike the beta2 integrins, the CD106-VLA-4 interaction can mediate both the initial tethering and rolling of lymphocytes on endothelium as well as their subsequent arrest and firm adhesion. CD106 expressed on non-vascular tissues has been implicated in the interaction of hematopoietic progenitors with bone marrow stromal cells, B cell binding to follicular dendritic cells, costimulation of T cells, and embryonic development. The monoclonal antibody 1.G11B1 inhibits in vitro binding of lymphocytes and monocytes to VCAM-1 on stimulated endothelium.